Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Capital Expenditures (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Capital Expenditures for 8 consecutive years, with $2000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Capital Expenditures fell 92.86% to $2000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $163000.0, a 28.35% increase, with the full-year FY2024 number at $250000.0, down 87.23% from a year prior.
  • Capital Expenditures was $2000.0 for Q2 2025 at Precision Biosciences, down from $64000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $1.7 million in Q2 2021 to a low of -$26000.0 in Q4 2023.
  • A 5-year average of $591388.9 and a median of $576500.0 in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: tumbled 104.11% in 2023, then surged 473.08% in 2024.
  • Precision Biosciences' Capital Expenditures stood at $1.5 million in 2021, then tumbled by 58.01% to $632000.0 in 2022, then crashed by 104.11% to -$26000.0 in 2023, then soared by 473.08% to $97000.0 in 2024, then crashed by 97.94% to $2000.0 in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Capital Expenditures are $2000.0 (Q2 2025), $64000.0 (Q1 2025), and $97000.0 (Q4 2024).